|
Table 1. Baseline characteristics of the population with Osteogenesis Imperfecta. This was a homogeneous sample with a mean age of 10.5 years. During the prospective follow-up of the patients, a bone chemistry panel was performed. |
||
|
Retrospective N = 38 n (%) |
Prospective N = 30 n (%) |
|
|
Demographic |
||
|
Age* |
10.8 ± 4.26 |
10.2 ± 4.30 |
|
Gender |
||
|
Female |
21 (55) |
13 (43) |
|
Male |
17 (45) |
17 (57) |
|
Size (cm)* |
NA |
109.34 ± 25.34 |
|
Weight (kg)* |
NA |
31.92 ± 26.70 |
|
Clinical Data |
||
|
Type of OI [silence classification] |
||
|
I |
18 (47) |
18 (60) |
|
III |
15 (40) |
9 (30) |
|
IV |
5 (13) |
3 (10) |
|
Wandering |
26 (68) |
22 (73) |
|
Blue sclera |
38 (100) |
18 (60) |
|
Dentinogenesis |
21 (55) |
20 (67) |
|
Total fractures before BP treatment (types)‡ |
||
|
I |
7 [4-9] |
6 [2-7] |
|
III |
23 [8-31] |
7 [3-25] |
|
IV |
30 [15-26] |
10 [3-22] |
|
Laboratory and cabinet |
||
|
Patients with DXA initial |
22 (55) |
30 (100) |
|
Laboratories* |
||
|
Creatinine |
NA |
0.42 ± 0.15 |
|
Albumin |
NA |
4.35 ± 0.22 |
|
Calcium |
NA |
9.56 ± 0.49 |
|
Phosphorus |
NA |
5.15 ± 0.77 |
|
Magnesium |
NA |
2.11 ± 0.23 |
|
Alkaline Phosphatase |
NA |
258 ± 90.9 |
|
25-OHD |
NA |
28.2 ± 14.06 |
|
* Data indicate mean ± standard deviation. ‡ Data expressed by range. BP = bisphosphonate. NA = not available. OI = osteogenesis imperfecta. |
||